Covid-19 Opportunity Still at Play for Novavax, Says Top Analyst

Delays for the regulatory filings of its Covid-19 vaccine NVX-CoV2373 (NUVAXOVID) have meant Novavax (NVAX) has been unable to get its offering out to the public yet. You would think that with other leading players firmly planted in the public and health policy makers’ consciousness, maybe the opportunity has already passed for last year’s outstanding performer.

However, in late-stage studies, the vaccine’s data has shown to be just as good as those of the leading approved vaccines….


Source link

About search

Check Also

European Stocks Drop With US Tech Rally Faltering: Markets Wrap – Yahoo Finance

European Stocks Drop With US Tech Rally Faltering: Markets Wrap – Yahoo Finance

[unable to retrieve full-text content]European Stocks Drop With US Tech Rally Faltering: Markets Wrap  Yahoo Finance …

Leave a Reply

Your email address will not be published. Required fields are marked *